

Publications

1. Al-Harbi NO, **Imam F**, Al-Harbi MM, Al-Shabanah OA, Alotaibi MR, As Sobeai HM, Afzal M, Kazmi I, Al Rikabi AC. Rutin inhibits carfilzomib-induced oxidative stress and inflammation via the NOS-mediated NF- κ B signaling pathway. *Inflammopharmacology*. 2019 Jan 1. doi: 10.1007/s10787-018-0550-5. [Epub ahead of print]. * Corresponding author **(Impact factor: 3.304)**
2. **Imam F**, Al-Harbi NO, Al-Harbi MM, Qamar W, Algerian K, Belali OM, Alsanea S, Alanazi AZ, Alhazzani K. Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries. *Int Immunopharmacol*. 2018 Nov 27;66:260-266. * Corresponding author **(Impact factor: 3.118)**
3. **Imam F**, Al-Harbi NO, Al-Harbi MM, Ansari MA, Al-Asmari AF, Ansari MN, Alanazi WA, Bahashwan S, Almutairi MM, Alshammari M, Khan MR, Alsaad MA, Alotaibi MR. Apremilast prevents doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF- κ B signaling pathways. *Pharmacological Reports*. 2018 March 27. [Epub ahead of print] * Corresponding author **(Impact factor: 2.787)**
4. Alshahrani SM, Alshetaili AS, Alalaiwe A, Alsulays BB, Anwer MK, Al-Shdefat R, **Imam F**, Shakeel F. Anticancer Efficacy of Self-Nanoemulsifying Drug Delivery System of Sunitinib Malate. *AAPS PharmSciTech*. 2018; 19(1): 123-133. **(Impact factor: 2.666)**
5. Alanazi A, Algefeley SG, Al-Hosaini KA, Korashy HM, **Imam F**, Nagi MN. Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen-induced hepatotoxicity in mice. *J Biochem Mol Toxicol*. 2017 Apr;31(4). [Epub 2016 Nov 30] **(Impact factor: 1.837)**
6. **Imam F**, Al-Harbi NO, Al-Harbi MM, Korashy HM, Ansari MA, Sayed-Ahmed MM, Nagi MN, Iqbal M, Khalid Anwer M, Kazmi I, Afzal M, Bahashwan S. Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF- κ B, Hypertrophic Gene Expression and Oxidative Stress. *Cardiovasc Toxicol*. 2017; 17(1):58-66 * Corresponding author **(Impact factor: 2.989)**
7. **Imam F**, Al-Harbi NO, Al-Harbi MM, Ansari MA, Almutairi MM, Alshammari M, Almukhlafi TS, Ansari MN, Algerian K, Ahmad SF. Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF- κ B and MAPK signaling in rats. *Toxicol Mech Methods*. 2016; 26(9): 700-708. * Corresponding author **(Impact factor: 1.994)**
8. Iqbal M, Ezzeldin E, Al-Rashood ST, **Imam F**, Al-Rashood KA. Determination of apremilast in rat plasma by UPLC-MS/MS in ESI-negative mode to avoid adduct ions formation. *Bioanalysis*. 2016 Jun 28. [Epub ahead of print] **(Impact factor: 2.478)**
9. Bakheet SA, Alhuraishi AM, Al-Harbi NO, Al-Hosaini KA, Al-Sharary SD, Attia MM, Alhoshani AR, Al-Shabanah OA, Al-Harbi MM, **Imam F**, Ahmad SF, Attia SM. Alleviation of Aflatoxin B1-Induced Genomic Damage by Proanthocyanidins via Modulation of DNA Repair. *J Biochem Mol Toxicol*. 2016; 30(11): 559-566. **(Impact factor: 1.837)**

10. Korashy HM, Ansari MA, Maayah ZH, **Imam F**, Raish M, Attafi IM, Alharbi NO, Moraished BA. Differential Effects of Sunitinib on the Expression Profiles of Xenobiotic-Metabolizing Enzymes and Transporters in Rat Liver and Kidneys. *Basic Clin Pharmacol Toxicol*. 2016 Aug;119(2):173-83. **(Impact factor: 2.659)**
11. **Imam F**, Al-Harbi NO, Al-Harbi MM, Ahmad SF, Ansari MA, Zoheir KMA, Iqbal M, Anwer K, Ali Alhoshani A, Attia SM. Diosmin downregulates the expression of T cell receptors, pro-inflammatory cytokines and NF-kB activation against LPS-induced acute lung injury in mice. *Pharmacol Res*. 2015; 102:1-11. * Corresponding author **(Impact factor: 4.897)**
12. Bhat MA, Al-Omar MA, Ansari MA, Zoheir KM, **Imam F**, Attia SM, Bakheet SA, Nadeem A, Korashy HM, Voronkov A, Berishvili V, Ahmad SF. Design and Synthesis of N-Arylphthalimides as Inhibitors of Glucocorticoid-Induced TNF Receptor-Related Protein, Proinflammatory Mediators, and Cytokines in Carrageenan-Induced Lung Inflammation. *J Med Chem*. 2015;58(22):8850-67. **(Impact factor: 6.253)**
13. Al-Harbi NO, **Imam F**, Nadeem A, Al-Harbi MM, Korashy HM, Sayed-Ahmed MM, Hafez MM, Al-Shabanah OA, Nagi MN, Bahashwan S. Riboflavin attenuates lipopolysaccharide-induced lung injury in rats. *Toxicol Mech Methods*. 2015; 25(5): 417-23. * Corresponding author **(Impact factor: 1.994)**
14. Al-Harbi NO, Nadeem A, Al-Harbi MM, **Imam F**, Al-Shabanah OA, Ahmad SF, Sayed-Ahmed MM, Bahashwan SA. Oxidative airway inflammation leads to systemic and vascular oxidative stress in a murine model of allergic asthma. *Int Immunopharmacol*. 2015; 26(1): 237-45. **(Impact factor: 3.118)**
15. Iqbal M, Khalil NY, **Imam F**, Khalid Anwer M. A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample. *J Thromb Thrombolysis*. 2015; 39(1): 79-88. **(Impact factor: 2.620)**
16. Sharma M, Khayyam UK, Imam F, Kumar V, Pillai KK, Behera D. Influence of honey on sputum conversion of new pulmonary tuberculosis patients receiving DOTS under revised national tuberculosis control program (RNTCP). *World Journal of Pharmaceutical Research*. 2015; 4(9): 437-443.
17. Khayyam UK, Muzammil S, Yunus M, Imam F. Epidemiological study of obesity in urban population based on body mass index. *Journal of Science and Pharmacy*. 2015; 5(2): 196-200.
18. Al-Harbi NO, **Imam F**, Al-Harbi MM, Iqbal M, Nadeem A, Al-Shahrah OA, Korashy HM, Al-Hosaini KA, Ahmed M, Bahashwan S. Treatment with aliskiren ameliorates tacrolimus-induced nephrotoxicity in rats. *J Renin Angiotensin Aldosterone Syst*. 2014 Apr 15. *Corresponding author **(Impact factor: 1.197)**
19. Al-Harbi NO, **Imam F**, Nadeem A, Al-Harbi MM, Iqbal M, Rahman S, Al-Hosaini KA, Bahashwan S. Protection against tacrolimus-induced cardiotoxicity in rats by olmesartan and aliskiren. *Toxicol Mech Methods*. 2014; 24(9):697-702. * Corresponding author **(Impact factor: 1.595)**
20. Al-Harbi NO, **Imam F**, Nadeem A, Al-Harbi MM, Iqbal M, Ahmad SF. Carbon tetrachloride-induced hepatotoxicity in rat is reversed by treatment with riboflavin *Int Immunopharmacol*. 2014; 21(2): 383-388. * Corresponding author **(Impact factor: 3.118)**

21. Al-Harbi NO, **Imam F**, Al-Harbi MM, Iqbal M, Nadeem A, Sayed-Ahmed MM, Alabidy AD, Almukhallafi AF. Olmesartan Attenuates Tacrolimus-Induced Biochemical and Ultrastructural Changes in Rat Kidney Tissue. *Biomed Res Int*. 2014; 2014: 607246. *Corresponding author (**Impact factor: 2.583**)
22. Nadeem A, Siddiqui N, Alharbi NO, Alharbi MM, **Imam F**. Acute glutathione depletion leads to enhancement of airway reactivity and inflammation via p38 MAPK-iNOS pathway in allergic mice. *Int Immunopharmacol*. 2014; 22(1): 222-229 (**Impact factor: 3.118**)
23. Nadeem A, Siddiqui N, Alharbi NO, Alharbi MM, **Imam F**, Sayed-Ahmed MM. Glutathione modulation during sensitization as well as challenge phase regulates airway reactivity and inflammation in mouse model of allergic asthma. *Biochimie*. 2014; 103: 61-70. (**Impact factor: 3.188**)
24. Saleem S, Shaharyar MA, Khusroo MJ, Ahmad P, Rahman R, Ahmad K, Alam MJ, Al-Harbi NO, Iqbal M, **Imam F**. Anticancer potential of rhamnocitrin 4'- β -d-galactopyranoside against N-diethylnitrosamine-induced hepatocellular carcinoma in rats. *Molecular and cellular biochemistry*. 2013; 384(1-2): 147-153. (**Impact factor: 2.561**)
25. Kazmi I, Afzal M, Rahman S, Iqbal M, **Imam F**, Anwar F. Antiobesity potential of ursolic acid stearyl glucoside by inhibiting pancreatic lipase. *European J Pharmacology*. 2013; 709(1-3):28-36. (**Impact factor: 3.040**)
26. Afzal M, Kazmi I, Khan R, Singh R, Pravez M, **Imam F**, Anwar F. Pharmacological Evaluation of Gatifloxacin in Chemically Induced Hepatocarcinogenesis: A New Tool for Hepato-cellularcarcinoma Treatment. *Journal of Cancer Science & Therapy*. 2013; 5(1): 18-22. (**Impact factor: 3.150***)
27. Ali MS, Alam MS, **Imam F**, Siddiqui MR. Topical nanoemulsion of turmeric oil for psoriasis: characterization, ex vivo and in vivo assessment. *International Journal of Drug Delivery*. 2012; 4(2): 184-197.
28. Afzal M, Gupta G, Kazmi I, Rahman M, Upadhyay G, Ahmad K, **Imam F**, Pravez M, Anwar F. Evaluation of anxiolytic activity of embelin isolated from *Embelia ribes*. *Biomedicine & Aging Pathology*. 2012; 2(2): 45-47.
29. Santanu M, Ravinder KM, Munsab A, Manju S, Najmi AK, **Imam F**. Associated socioeconomic status with illness behavior in tuberculosis patients undergoing DOTS therapy. *Indian Journal of Pharmacy Practice*. 2012; 5(3): 45-48.
30. Alam MS, Ali MS, Alam N, Alam MI, Anwer T, **Imam F**, Daud M, Ali MRS, Shamim M. Design and Characterization of Nanostructure Topical Gel of Betamethasone Dipropionate for Psoriasis. *Journal of Applied Pharmaceutical Science*. 2012; 2(10): 148-158.
31. Ansari MS, Khayyam UK, Sharma M, **Imam F**, Behera D. The role of socio-economic factors responsible for non-compliance of directly observed treatment short-course among tuberculosis patients. *Journal of Medicine and Health Sciences*. 2011; 18(2): 78-86.

32. Khayyam UK, Muzammil S, **Imam F**. Distribution of obesity among male and female population based on body mass index and relative body weight. *J Hosp. Clin. Pharmacy*. 2011; 1(2): 1-6.
33. Khayyam UK, Muzammil S, **Imam F**, Ali M, Anjum R, Anwer MK. An epidemiological study of obesity according to physical activity and family history of disease. *J Hosp. Clin. Pharmacy*. 2010; 1(1): 1-7.
34. Khalid UK, **Imam F**, Sharma M, Pillai K, Sarin R, Behera D. Pyrazinamide Induced Maculopapular Rash: The Commonly Used First Line Antitubercular Drug. *Indian J. Dermatology*. 2010; 55(4): 384-86.
* Corresponding author
35. Anwer T, Sharma M, Iqbal M, **Imam F**, Pillai KK. Comparative analysis of the protective effects of Melatonin and Silamarine on lipid peroxidation and Dyslipidemia in STZ-induced diabetic rats. *Hamdard Medicus*. 2009; 52(3): 58-61
36. Sharma M, Ashraf, ZR, Pillai KK, Ahmad D, Imam F. Protective effect of alpha-ketoglutarate on heart against doxorubicin induced cardiotoxicity in rats. *Indian Journal of Pharmacology*. 2008; 40: 166-166. (Abstract).
37. Sharma M, Khayyam UK, Kumar V, **Imam F**, Pillai KK, Behera D. Influence of Honey on Adverse Drug Reactions due to Anti-tuberculosis Drugs in Pulmonary Tuberculosis Patients. *Cont. J Pharmacol. Toxicol. Research*. 2008; 2: 6-11.
38. Sharma H, Aqil M, **Imam F**, Hussain A, Alam MS, Kapur P, Pillai KK, A Pharmacovigilance Study in the department of medicine of a University teaching hospital. *Pharmacy Practice*. 2007; 5: 46-49.
39. Aqil M, **Imam F**, Hussain A, Kapur P, Pillai KK. A Pharmacovigilance Study for Monitoring Adverse Drug Reactions with Antihypertensive Agents at a South Delhi Hospital. *Int. J Pharmacy Pract*. 2006; 14 (4): 311-13.

Invited Review

1. **Imam F**, Anwer MK, Iqbal M, Alam M, Khayyam UK, Sharma M. Tuberculosis: Brief overview and its shifting paradigm for management in India. *Int. J Pharmacol*. 2010; 1(1): 755-783.